



EY Entrepreneur of the year-2013



FROST & SULLIVAN  
2013 BEST PRACTICES AWARD  
Competitive Strategy Leadership Award, India



Business today/YES bank  
Excellence Awards-2013



**Date: 31<sup>st</sup> October, 2022**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: TRANSCRIPT OF ANALYST AND INVESTOR CALL**

Dear Sir/Madam,

This is to inform that the transcript of the Analyst and Investor call which was held after the announcement of financial results for the quarter ended, 30<sup>th</sup> September 2022 is available on our website URL <https://eris.co.in/financials/>

(File name: Transcript of the Analyst and Investor Conference Call Q2FY23).

Thanking You,

**For Eris Lifesciences Limited**

---

**Milind Talegaonkar**  
**Company Secretary and Compliance Officer**  
**Mem. No. A26493**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867